{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:46:13Z","timestamp":1794717973444,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 01KG0705"],"award-info":[{"award-number":["FKZ 01KG0705"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 01KG0705"],"award-info":[{"award-number":["FKZ 01KG0705"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 01KG0705"],"award-info":[{"award-number":["FKZ 01KG0705"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 01KG0705"],"award-info":[{"award-number":["FKZ 01KG0705"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 01KG0705"],"award-info":[{"award-number":["FKZ 01KG0705"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 01KG0705"],"award-info":[{"award-number":["FKZ 01KG0705"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 01KG0705"],"award-info":[{"award-number":["FKZ 01KG0705"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1038\/s41375-020-0838-5","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T08:02:27Z","timestamp":1588838547000},"page":"143-155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial"],"prefix":"10.1038","volume":"35","author":[{"name":"for the ACT-2 study investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald G.","family":"Wulf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Ziepert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"D\u2019Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Relander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3246-4470","authenticated-orcid":false,"given":"Antonio","family":"Pezzutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josee M.","family":"Zijlstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Van Den","family":"Neste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieternella J.","family":"Lugtenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette K.","family":"Doorduijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel van","family":"Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustaaf W.","family":"van Imhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Zettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Braulke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Nickelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gaulard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6982-8218","authenticated-orcid":false,"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"838_CR1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"838_CR2","doi-asserted-by":"crossref","unstructured":"Wang SS, Vose J. Epidemiology and prognosis of T-Cell lymphoma. In: Foss F editor. T-Cell lymphomas. Springer; New York 2013.","DOI":"10.1007\/978-1-62703-170-7_2"},{"key":"838_CR3","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418\u201325.","journal-title":"Blood"},{"key":"838_CR4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bjh.13202","volume":"168","author":"AM Petrich","year":"2015","unstructured":"Petrich AM, Helenowski IB, Bryan LJ, Rozell SA, Galamaga R, Nabhan C. Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era. Br J Haematol. 2015;168:708\u201318.","journal-title":"Br J Haematol"},{"key":"838_CR5","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","volume":"30","author":"D Sibon","year":"2012","unstructured":"Sibon D, Fournier M, Briere J, Lamant L, Haioun C, Coiffier B, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte trials. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30:3939\u201346.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"838_CR6","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","volume":"115","author":"M Sieniawski","year":"2010","unstructured":"Sieniawski M, Angamuthu N, Boyd K, Chasty R, Davies J, Forsyth P, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115:3664\u201370.","journal-title":"Blood"},{"key":"838_CR7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","volume":"151","author":"A Simon","year":"2010","unstructured":"Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151:159\u201366.","journal-title":"Br J Haematol"},{"key":"838_CR8","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","volume":"20","author":"M Nickelsen","year":"2009","unstructured":"Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, Leithaeuser M, et al. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol. 2009;20:1977\u201384.","journal-title":"Ann Oncol"},{"key":"838_CR9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106\u201313.","journal-title":"J Clin Oncol"},{"key":"838_CR10","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093\u201399.","journal-title":"J Clin Oncol"},{"key":"838_CR11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2012.09.002","volume":"13","author":"MH Voss","year":"2013","unstructured":"Voss MH, Lunning MA, Maragulia JC, Papadopoulos EB, Goldberg J, Zelenetz AD, et al. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma, Myeloma Leuk. 2013;13:8\u201314.","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"838_CR12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","volume":"172","author":"RH Advani","year":"2016","unstructured":"Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Br J Haematol. 2016;172:535\u201344.","journal-title":"Br J Haematol"},{"key":"838_CR13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631\u201336.","journal-title":"J Clin Oncol"},{"key":"838_CR14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","volume":"131","author":"JE Amengual","year":"2018","unstructured":"Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018;131:397\u2013407.","journal-title":"Blood"},{"key":"838_CR15","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1038\/sj.onc.1210376","volume":"26","author":"B Coiffier","year":"2007","unstructured":"Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26:3603\u201313.","journal-title":"Oncogene"},{"key":"838_CR16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2009.07606.x","volume":"145","author":"L Jiang","year":"2009","unstructured":"Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol. 2009;145:173\u20139.","journal-title":"Br J Haematol"},{"key":"838_CR17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1440-1827.2007.02195.x","volume":"58","author":"K Karube","year":"2008","unstructured":"Karube K, Aoki R, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, et al. Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int. 2008;58:89\u201397.","journal-title":"Pathol Int"},{"key":"838_CR18","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496\u2013504.","journal-title":"Blood"},{"key":"838_CR19","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","volume":"24","author":"P Went","year":"2006","unstructured":"Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:2472\u20139.","journal-title":"J Clin Oncol"},{"key":"838_CR20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/0022-2836(88)90214-8","volume":"203","author":"L Riechmann","year":"1988","unstructured":"Riechmann L, Foote J, Winter G. Expression of an antibody Fv fragment in myeloma cells. J Mol Biol. 1988;203:825\u20138.","journal-title":"J Mol Biol"},{"key":"838_CR21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/332323a0","volume":"332","author":"L Riechmann","year":"1988","unstructured":"Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332:323\u20137.","journal-title":"Nature"},{"key":"838_CR22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","volume":"22","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998;22:185\u201391.","journal-title":"Leuk Res"},{"key":"838_CR23","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bbmt.2017.02.007","volume":"23","author":"K Green","year":"2017","unstructured":"Green K, Pearce K, Sellar RS, Jardine L, Nicolson PLR, Nagra S, et al. Impact of Alemtuzumab Scheduling on Graft-versus-Host disease after unrelated donor fludarabine and melphalan allografts. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2017;23:805\u201312.","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"key":"838_CR24","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1586\/14737140.8.4.525","volume":"8","author":"K Boyd","year":"2008","unstructured":"Boyd K, Dearden CE. Alemtuzumab in the treatment of chronic lymphocytic lymphoma. Expert Rev anticancer Ther. 2008;8:525\u201333.","journal-title":"Expert Rev anticancer Ther"},{"key":"838_CR25","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1200\/JCO.2011.35.9695","volume":"30","author":"AR Pettitt","year":"2012","unstructured":"Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol. 2012;30:1647\u201355.","journal-title":"J Clin Oncol"},{"key":"838_CR26","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","volume":"103","author":"G Enblad","year":"2004","unstructured":"Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103:2920\u20134.","journal-title":"Blood"},{"key":"838_CR27","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110:2316\u201323.","journal-title":"Blood"},{"key":"838_CR28","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","volume":"22","author":"HC Kluin-Nelemans","year":"2011","unstructured":"Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, van Putten WL, Luten M, Oudejans J, et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol. 2011;22:1595\u20131600.","journal-title":"Ann Oncol"},{"key":"838_CR29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00277-013-1880-4","volume":"92","author":"C Binder","year":"2013","unstructured":"Binder C, Ziepert M, Pfreundschuh M, Duhrsen U, Eimermacher H, Aldaoud A, et al. CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial. Ann Hematol. 2013;92:1521\u20131528.","journal-title":"Ann Hematol"},{"key":"838_CR30","doi-asserted-by":"crossref","unstructured":"d\u2019Amore F, Lepp\u00e4 S, Silva MGd, Relander T, Lauritzsen GF, Brown PDN, et al. Final analysis of the front-line phase III randomized ACT-1 trial in younger patients with systemic peripheral T-cell lymphoma treated with CHOP chemotherapy with or without Alemtuzumab and consolidated by autologous hematopoietic stem cell transplant. Blood. 2018;132 Suppl 1: 998.","DOI":"10.1182\/blood-2018-99-110429"},{"issue":"Suppl 15","key":"838_CR31","first-page":"8507","volume":"33","author":"N Schmitz","year":"2015","unstructured":"Schmitz N, Nickelsen M, Altmann B, Ziepert M, Bouabdallah K, Gisselbrecht C, et al. Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: results of the interim analysis of the AATT trial. J Clin Oncol. 2015;33(Suppl 15):8507.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"838_CR32","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2018-99-112076","volume":"132","author":"B Altmann","year":"2018","unstructured":"Altmann B, Wulf G, Truemper L, d\u2019Amore F, Relander T, Toldbod H, et al. Alemtuzumab added to CHOP for treatment of peripheral T-Cell lymphoma (PTCL) in previously untreated young and elderly patients: pooled analysis of the international ACT-1\/2 phase III trials. Blood. 2018;132(Suppl 1):1622.","journal-title":"Blood"},{"key":"838_CR33","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"838_CR34","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.","journal-title":"J Clin Oncol"},{"key":"838_CR35","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124:1570\u20137.","journal-title":"Blood"},{"key":"838_CR36","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","volume":"12","author":"SJ Rodig","year":"2006","unstructured":"Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res: Off J Am Assoc Cancer Res. 2006;12:7174\u20139.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"838_CR37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05789.x","volume":"132","author":"KA Thursky","year":"2006","unstructured":"Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol. 2006;132:3\u201312.","journal-title":"Br J Haematol"},{"key":"838_CR38","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2007-03-080010","volume":"111","author":"S O\u2019Brien","year":"2008","unstructured":"O\u2019Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008;111:1816\u20139.","journal-title":"Blood"},{"key":"838_CR39","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433\u201344.","journal-title":"N Engl J Med"},{"key":"838_CR40","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1055\/s-0035-1562902","volume":"36","author":"NM Clark","year":"2015","unstructured":"Clark NM, Grim SA, Lynch JP 3rd. Posaconazole: use in the prophylaxis and treatment of fungal infections. Semin Respiratory Crit Care Med. 2015;36:767\u201385.","journal-title":"Semin Respiratory Crit Care Med"},{"key":"838_CR41","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2006-04-017632","volume":"108","author":"J Dupuis","year":"2006","unstructured":"Dupuis J, Emile JF, Mounier N, Gisselbrecht C, Martin-Garcia N, Petrella T, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) study. Blood. 2006;108:4163\u20139.","journal-title":"Blood"},{"key":"838_CR42","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/ijc.30566","volume":"140","author":"BM Haverkos","year":"2017","unstructured":"Haverkos BM, Huang Y, Gru A, Pancholi P, Freud AG, Mishra A, et al. Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas. Int J Cancer. 2017;140:1899\u2013906.","journal-title":"Int J Cancer"},{"key":"838_CR43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1309\/6UTX-GVC0-12ND-JJEU","volume":"117","author":"A Zettl","year":"2002","unstructured":"Zettl A, Lee SS, Rudiger T, Starostik P, Marino M, Kirchner T, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol. 2002;117:368\u201379.","journal-title":"Am J Clin Pathol"},{"key":"838_CR44","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1080\/10428190600763348","volume":"47","author":"AA Abou-Elella","year":"2006","unstructured":"Abou-Elella AA, Nifong TP. Composite EBV negative peripheral T-cell lymphoma and diffuse large B-cell lymphoma involving the ileum: a case report and a systematic review of the literature. Leuk Lymphoma. 2006;47:2208\u201317.","journal-title":"Leuk Lymphoma"},{"key":"838_CR45","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2007.06725.x","volume":"138","author":"K Willenbrock","year":"2007","unstructured":"Willenbrock K, Brauninger A, Hansmann ML. Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol. 2007;138:733\u20139.","journal-title":"Br J Haematol"},{"key":"838_CR46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2015.09.033","volume":"48","author":"JC Hoffmann","year":"2016","unstructured":"Hoffmann JC, Chisholm KM, Cherry A, Chen J, Arber DA, Natkunam Y, et al. An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified. Hum Pathol. 2016;48:9\u201317.","journal-title":"Hum Pathol"},{"key":"838_CR47","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12253-009-9233-2","volume":"16","author":"G Smuk","year":"2010","unstructured":"Smuk G, Illes A, Keresztes K, Kereskai L, Marton B, Nagy Z, et al. Pheno- and genotypic features of Epstein-Barr virus associated B-cell lymphoproliferations in peripheral T-cell lymphomas. Pathol Oncol Res. 2010;16:377\u201383.","journal-title":"Pathol Oncol Res"},{"key":"838_CR48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jcv.2014.01.005","volume":"59","author":"H Gill","year":"2014","unstructured":"Gill H, Hwang YY, Chan TS, Pang AW, Leung AY, Tse E, et al. Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab. J Clin Virol. 2014;59:255\u20138.","journal-title":"J Clin Virol"},{"key":"838_CR49","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdq359","volume":"22","author":"G Gutierrez-Garcia","year":"2011","unstructured":"Gutierrez-Garcia G, Garcia-Herrera A, Cardesa T, Martinez A, Villamor N, Ghita G, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2011;22:397\u2013404.","journal-title":"Ann Oncol"},{"key":"838_CR50","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31:240\u20136.","journal-title":"J Clin Oncol"},{"key":"838_CR51","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","volume":"9","author":"A Lopez-Guillermo","year":"1998","unstructured":"Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo JM, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol. 1998;9:849\u201355.","journal-title":"Ann Oncol"},{"key":"838_CR52","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474\u20139.","journal-title":"Blood"},{"key":"838_CR53","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","volume":"27","author":"SJ Kim","year":"2009","unstructured":"Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell Lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol. 2009;27:6027\u201332.","journal-title":"J Clin Oncol"},{"key":"838_CR54","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402\u20138.","journal-title":"Blood"},{"key":"838_CR55","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12185-013-1383-z","volume":"98","author":"Y Torimoto","year":"2013","unstructured":"Torimoto Y, Sato K, Ikuta K, Hayashi T, Hirayama Y, Inamura J, et al. A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group. Int J Hematol. 2013;98:171\u20138.","journal-title":"Int J Hematol"},{"key":"838_CR56","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","volume":"49","author":"AN Abouyabis","year":"2008","unstructured":"Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma. 2008;49:2099\u2013107.","journal-title":"Leuk Lymphoma"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0838-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0838-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0838-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:40:27Z","timestamp":1684604427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0838-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["838"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0838-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]},"assertion":[{"value":"14 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}